Muscle-invasie urothelial carcinoma MIBC, patient preference,
Conditions
Interventions
None listed
Sponsors
Ito Hiroaki
Ho Pei-Ran
Ono Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients residing in Japan and able to speak/read Japanese for the interview/survey 2. Patients aged 18 years or more at the time of consent 3. Patients with a pathological diagnosis of MIBC (either of the following): - ypT2-ypT4a or ypN+ MIBC, with prior neoadjuvant cisplatin chemotherapy and who underwent radical cystectomy - pT3-pT4a or pN+ MIBC, without prior neoadjuvant cisplatin chemotherapy and who underwent radical cystectomy 4. Patients who have not received any treatment related to MIBC after radical cystectomy 5. Patients who are able and willing to provide written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: 1.Patient is determined by the physician as being unsuitable for the study 2.Patient has a confirmed diagnosis of other primary cancer(s) at the time of obtaining consent 3.Patient is currently participating in a MIBC clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To identify important treatment attributes for post-radical cystectomy (RC) treatment for patients with MIBC (Muscle-Invasive Bladder Cancer) in Japan. 2.To assess the relative importance of treatment attributes for post-RC treatment, such as disease-free survival, side effects, frequency of dosage etc. | — |
Secondary
| Measure | Time frame |
|---|---|
| To consider potential differences in treatment preferences amongst MIBC patients in Japan with differing demographic or clinical characteristics | — |
Contacts
Public ContactHiroaki Ito
Bristol-Myers Squibb K.K.
Outcome results
None listed